6.17

5.65% 0.33

Atara Biotherapeutics Inc (ATRA)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt ATRA? Forum Prognose

Schlusskurs vom Vortag:

$5.84

Offen:

$5.84

24-Stunden-Volumen:

23,959

Relative Volume:

0.14

Marktkapitalisierung:

$34.27M

Einnahmen:

$100.44M

Nettoeinkommen (Verlust:

$-133.16M

KGV:

-0.2395

EPS:

-25.76

Netto-Cashflow:

$-94.85M

1W Leistung:

+16.42%

1M Leistung:

-13.95%

6M Leistung:

-34.22%

1J Leistung:

-65.48%

1-Tages-Spanne:

$5.62

$6.18

1-Wochen-Bereich:

$5.1559

$6.18

52-Wochen-Spanne:

$5.005

$19.00

Atara Biotherapeutics Inc Stock (ATRA) Company Profile

Firmenname

Atara Biotherapeutics Inc

Sektor

Healthcare (1151)

Branche

Biotechnology (660)

Telefon

805-623-4211

Adresse

1280 RANCHO CONEJO BLVD, THOUSAND OAKS, CA

Mitarbeiter

153

Twitter

@Atarabio

Nächster Verdiensttermin

2024-11-18

Neueste SEC-Einreichungen

ATRA's Discussions on Twitter

Vergleichen Sie ATRA mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
ATRA Atara Biotherapeutics Inc	6.17	34.27M	100.44M	-133.16M	-94.85M	-25.76
VRTX Vertex Pharmaceuticals Inc	489.10	127.47B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	563.16	62.43B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	596.20	37.03B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	234.56	31.06B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	230.98	26.16B	3.81B	-644.79M	-669.77M	-6.24

Atara Biotherapeutics Inc Stock (ATRA) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2023-11-09	Herabstufung	Evercore ISI	Outperform → In-line
2023-11-09	Herabstufung	H.C. Wainwright	Buy → Neutral
2023-11-09	Herabstufung	Mizuho	Buy → Neutral
2022-07-20	Herabstufung	Citigroup	Neutral → Sell
2022-07-13	Herabstufung	JP Morgan	Overweight → Neutral
2022-07-13	Herabstufung	Stifel	Buy → Hold
2022-05-10	Herabstufung	Citigroup	Buy → Neutral
2021-05-13	Hochstufung	JP Morgan	Neutral → Overweight
2020-12-09	Herabstufung	Citigroup	Buy → Neutral
2020-12-08	Bestätigt	H.C. Wainwright	Buy
2020-11-10	Bestätigt	H.C. Wainwright	Buy
2020-06-30	Eingeleitet	Evercore ISI	Outperform
2020-06-15	Eingeleitet	H.C. Wainwright	Buy
2020-04-23	Hochstufung	Citigroup	Neutral → Buy
2019-11-08	Herabstufung	JP Morgan	Overweight → Neutral
2019-09-27	Herabstufung	Goldman	Neutral → Sell
2019-09-16	Herabstufung	Jefferies	Buy → Hold
2019-06-04	Hochstufung	Citigroup	Sell → Neutral
2019-05-30	Eingeleitet	ROTH Capital	Buy
2019-05-23	Eingeleitet	Stifel	Buy
2019-01-23	Eingeleitet	Mizuho	Buy
2018-04-10	Eingeleitet	JP Morgan	Overweight
2018-03-16	Eingeleitet	Guggenheim	Neutral
2018-03-05	Bestätigt	Jefferies	Buy
2018-02-28	Herabstufung	JMP Securities	Mkt Outperform → Mkt Perform
2018-02-15	Herabstufung	Citigroup	Neutral → Sell
2018-01-03	Hochstufung	Citigroup	Sell → Neutral
2017-10-06	Fortgesetzt	Goldman	Neutral

Alle ansehen

Atara Biotherapeutics Inc Aktie (ATRA) Neueste Nachrichten

Apr 08, 2025

Trial misses sink cancer stocks in Q1: Mersana, Cargo, Mural fall - BioWorld MedTech

Apr 08, 2025

Apr 07, 2025

Layoff Tracker: Spark Lays Off 298 Employees - BioSpace

Apr 07, 2025

Atara Biotherapeutics stock hits 52-week low at $5.3 - Investing.com

Apr 07, 2025

Apr 04, 2025

How the (ATRA) price action is used to our Advantage - news.stocktradersdaily.com

Apr 04, 2025

Atara Biotherapeutics IncOn March 31, Entered Amendment To Commercialization Agreement With Pierre FabreSEC Filing - marketscreener.com

Apr 04, 2025

Epstein-Barr Virus (EBV) Market Growth 2025: Trends, Consumer - openPR.com

Apr 04, 2025

Mar 26, 2025

Atara Biotherapeutics Faces Potential Liquidation: Strategic Decisions Crucial for Investor Outcomes - MSN

Mar 26, 2025

Mar 25, 2025

Long Term Trading Analysis for (ATRA) - news.stocktradersdaily.com

Mar 25, 2025

Mar 23, 2025

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World

Mar 23, 2025

Mar 19, 2025

Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Mar 19, 2025

Atara Biotherapeutics (NASDAQ:ATRA) Stock Crosses Below 50 Day Moving Average – Should You Sell? - Defense World

Mar 19, 2025

Mar 17, 2025

Multiple Sclerosis Treatment Market 2034: EMA, PDMA, FDA Approval, Clinical Trials, Medication, Epidemiology, Prevalence, Therapies and Companies by DelveInsight - The Globe and Mail

Mar 17, 2025

Mar 15, 2025

(ATRA) Investment Report - news.stocktradersdaily.com

Mar 15, 2025

Mar 13, 2025

Atara Biotherapeutics (ATRA) Moves to Buy: Rationale Behind the Upgrade - Yahoo Finance

Mar 13, 2025

Mar 12, 2025

Atara Biotherapeutics (NASDAQ:ATRA) Given Buy Rating at Canaccord Genuity Group - Defense World

Mar 12, 2025

Mar 11, 2025

Atara Biotherapeutics: Strategic Focus on Ebvallo BLA Resubmission and Market Position Enhancement - TipRanks

Mar 11, 2025

Mar 10, 2025

Atara Biotherapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Operational Progress - BioSpace

Mar 07, 2025